ENDOWAVE LIMITED

Their core work

Endowave Limited is a Dublin-based medical device SME developing a bronchoscopic microwave ablation system for the treatment of lung cancer. Their technology delivers targeted thermal energy through a bronchoscope to destroy tumors from inside the airway, avoiding open surgery or radiation. Their EU-funded trajectory — from a Phase 1 feasibility study (ENDOWAVE, 2019) to a full Innovation Action for commercialisation (TABLA, 2020–2023) — shows they have moved from concept validation to a product ready for clinical and market entry. Their work sits at the intersection of interventional pulmonology, oncology, and medical device engineering.

What they specialise in

How they've shifted over time

Endowave's H2020 history is a textbook SME scale-up arc compressed into two projects. In 2019 they used SME Instrument Phase 1 (€50k) to validate the technical and commercial feasibility of their bronchoscopic microwave concept — at that stage no detailed keywords were recorded, consistent with an early-stage scoping exercise. By 2020 they had secured a €2M Innovation Action (TABLA), with a fully elaborated technical vocabulary: lung cancer, thermal ablation, transbronchial, microwave. The shift is not a change in focus — it is a deepening: the same core idea maturing from hypothesis to engineered product ready for commercialisation.

Endowave is on a clear trajectory toward clinical and commercial launch of their bronchoscopic microwave ablation device; a future partner would most likely be needed for clinical trials, regulatory affairs, distribution, or hospital adoption rather than early-stage R&D.

How they like to work

Endowave leads every project they enter — both H2020 projects were won as coordinator, which is unusual for an SME and signals strong project management and grant-writing capability. They work in small, tightly focused consortia (4 unique partners across 3 countries), consistent with a product-development model where each partner fills a specific gap rather than a broad research network. Working with them likely means joining a lean, goal-oriented team where Endowave drives the agenda and timeline.

Endowave has collaborated with 4 distinct partners across 3 countries, a deliberately small footprint reflecting their product-focused rather than research-network approach. Their partnerships are almost certainly clinical, engineering, or regulatory in nature, though specific partner identities are not in the available data.

What sets them apart

Endowave occupies a very specific niche: bronchoscopic (not surgical, not percutaneous) microwave ablation for lung cancer — a modality that allows treatment of tumors inaccessible to conventional ablation probes or too risky for surgery. As a twice-coordinating SME that has already cleared the Phase 1 feasibility gate and secured €2M for commercialisation, they are further along the development curve than most comparable research-stage players. A consortium builder looking for a lung oncology device company with demonstrated execution capacity and a commercially oriented roadmap would find few equivalents at this stage in the EU SME landscape.

Highlights from their portfolio

• TABLA
  At €2,033,553 under the Innovation Action scheme, TABLA is the flagship project — a full development-and-commercialisation push for the transbronchial lung ablation device, making it the defining project of Endowave's EU portfolio.
• ENDOWAVE
  The SME Instrument Phase 1 feasibility grant (€50k) that de-risked the concept and directly enabled the much larger TABLA award — a textbook example of the SME instrument as a stepping stone.